ClotCare: Blood Clots, Stroke, Heart Attack
Monday, March 27, 2017
Home   |   DVT/PE   |   Blood Clots   |   Coumadin/Warfarin   |   New Patients   |   Self Testing   |   Email List   |   Donate

Pick a Topic:

Find info on a:

We subscribe to the HONcode principles of the HON Foundation. Click to verify.
ClotCare complies with the HONcode standard for trustworthy health
information:
verify here.

ClotCare is a member of the Coalition to Prevent Deep Vein Thrombosis (DVT Coalition)  ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.

Advisories Against the Use of Clopidogrel (Plavix) with Proton Pump Inhibitors and Other Medications

Henry I. Bussey, Pharm.D. with input from Sarah Spinler, Pharm.D., and Melissa Smith.
November, 2010

ClotCare editorial board member Sarah Spinler, Pharm.D. recently brought to my attention both the FDA Advisory (see fda.gov/Safety/MedWatch/SafetyInformation/
SafetyAlertsforHumanMedicalProducts/ucm190848.htm
) and the change in the clopidogrel (Plavix) package insert (see products.sanofi-aventis.us/PLAVIX/PLAVIX.html) advising clinicians to avoid the use of Clopidogrel and omeprazole (Prilosec), and perhaps several other agents. The reason for the warning is that these agents are known to inhibit the CYP 2C19 hepatic enzyme that is responsible for converting clopidogrel to its active metabolite. Reduced conversion of clopidogrel to its active metabolite can reduce the therapeutic effect of clopidogrel and increase the risk of cardiovascular events. Even though reports have questioned the clinical impact of this interaction with various medications and in various patient groups, the FDA advisory and the change in the package insert would appear to carry legal status that clinicians should consider when using clopidogrel.

Dr. Spinler and Melissa Smith (a Pharm.D. student at the University of the Sciences in Philadelphia) provided ClotCare with permission to share the nice table below that they developed to help clinicians at their institution avoid using clopidogrel with the medications identified in the FDA advisory. (ClotCare visitors are welcome to print the table - as well as any other content on ClotCare - to use for improving patient care in their practices.)

Clopidogrel (Plavix) and Proton Pump Inhibitors: Interactions to Know
Ask a question about blood clots or anticoagulant medications Have questions? Ask ClotCare. Send questions by email to webmaster@clotcare.org.

ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters.

Blood Clot Activities Calendar

New Postings:

Seeking Patients Taking Warfarin (Coumadin) for a Brief Survey

Click here to view full list of new postings
ClotCare Home | New Postings | Patient Postings | Clinician Postings | Join Our Email List | Useful Web Links
CE Opportunities | Training Programs | DVT & PE Stories | Editorial Board | Financial Support
About ClotCare | DVT Coalition | Donate to ClotCare | Contact Us
Key topics discussed on ClotCare include: Blood Clots | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE) | Atrial Fibrillation (A. Fib or AF) | Heart Attack | Stroke | Transient Ischemic Attack (TIA) | Mini Stroke | Bleeding Complications | Vascular Surgery | Surgical Blood Clot Removal | Warfarin | Coumadin | Lovenox | Low Molecular Weight Heparin (LMWH) | Heparin | Anticoagulants | Plavix | Aspirin | Antiplatelets | Blood Thinners
Copyright 2000-2014 by ClotCare. All rights reserved.
Terms, Conditions, & Privacy | Image Copyright Information
19260 Stone Oak Parkway, Suite 101 | San Antonio, TX 78258 | 210-495-4335
Send comments to webmaster@clotcare.org.
Monday, March 27, 2017